Katsuyuki Kiura

List of Publications by Year
in descending order

254 papers	6,852 citations	126907 33 h-index	71685 76 g-index
261 all docs	261 docs citations	261 times ranked	7286 citing authors

#	Article	IF	Citations
1	Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan. Internal Medicine, 2022, 61, 379-383.	0.7	1
2	Protective effects of neuropeptide Y against elastase-induced pulmonary emphysema. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, , .	2.9	0
3	Identification of targetable kinases in idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, 20.	3.6	8
4	Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. BMC Cancer, 2022, 22, 342.	2.6	2
5	Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society. JTO Clinical and Research Reports, 2022, 3, 100317.	1.1	1
6	First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1869-1877.	2.5	5
7	<scp>Shortâ€term</scp> safety of an <scp>antiâ€severe</scp> acute respiratory syndrome coronavirus 2 messenger <scp>RNA</scp> vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study. Thoracic Cancer, 2022, 13, 453-459.	1.9	6
8	Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia. Respiratory Medicine Case Reports, 2022, 37, 101662.	0.4	2
9	Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801. International Journal of Clinical Oncology, 2022, 27, 1139-1144.	2.2	7
10	Three doses of mRNA COVIDâ€19 vaccine protects from SARSâ€CoVâ€2 infections in Japan. Journal of Internal Medicine, 2022, 292, 687-689.	6.0	2
11	Preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: An open-label, randomized, phase II study.. Journal of Clinical Oncology, 2022, 40, TPS12141-TPS12141.	1.6	0
12	Afatinib (Afa) + bevacizumab (Bev) versus afatinib alone as first-line treatment of patients with EGFR-mutated advanced non-squamous NSCLC: Primary analysis of the multicenter, randomized, phase II studyâ€”AfaBev-CS study.. Journal of Clinical Oncology, 2022, 40, 9112-9112.	1.6	2
13	CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer. Cancer Immunology Research, 2022, 10, 1111-1126.	3.4	10
14	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications, 2022, 2, 739-753.	1.7	2
15	Demand for weekend outpatient chemotherapy among patients with cancer in Japan. Supportive Care in Cancer, 2021, 29, 1287-1291.	2.2	4
16	Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 101-106.	4.2	26
17	Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer. Japanese Journal of Clinical Oncology, 2021, 51, 279-286.	1.3	7
18	Randomized study comparing mannitol with furosemide for the prevention of cisplatinâ€induced renal toxicity in nonâ€small cell lung cancer: The OLCSG1406 trial. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 101-108.	1.1	7

#	Article	IF	Citations
19	Novel prospective umbrellaâ€type lung cancer registry study for clarifying clinical practice patterns: <scp>CSâ€Lung</scp>â€003 study protocol. Thoracic Cancer, 2021, 12, 725-731.	1.9	2
20	A PET/CT volumetric parameter predicts prognosis of nonâ€'small cell lung cancer treated using preoperative chemoradiotherapy and surgery: A retrospective case series study. Molecular and Clinical Oncology, 2021, 14, 73.	1.0	3
21	Lung stereotactic body radiation therapy for elderly patients agedâ€‰â‰¥â€‰80Âyears with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study. Radiation Oncology, 2021, 16, 39.	2.7	10
22	A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401. Supportive Care in Cancer, 2021, 29, 5237-5244.	2.2	0
23	Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. Respiratory Investigation, 2021, 59, 240-246.	1.8	3
24	A case of interstitial pneumonia associated with systemic sclerosis and primary peritoneal serous carcinoma successfully treated with cyclophosphamide. International Cancer Conference Journal, 2021, 10, 197-200.	0.5	1
25	Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3749-3755.	2.5	6
26	VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogeneâ€driven nonâ€smallâ€cell lung cancers. Cancer Science, 2021, 112, 1853-1864.	3.9	29
27	Interstitial Pneumonia Secondary to Hermansky-Pudlak Syndrome Type 4 Treated with Different Antifibrotic Agents. Internal Medicine, 2021, 60, 783-788.	0.7	3
28	The 61st Annual Meeting of the Japan Lung Cancer Society: Eradication of lung cancer 2020. Okayama Igakkai Zasshi, 2021, 133, 80-82.	0.0	0
29	Sarcopenia is related to poor prognosis in patients after trimodality therapy for locally advanced non-small cell lung cancer. International Journal of Clinical Oncology, 2021, 26, 1450-1460.	2.2	4
30	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. Japanese Journal of Clinical Oncology, 2021, 51, 956-965.	1.3	6
31	Loss of IL-33 enhances elastase-induced and cigarette smoke extract-induced emphysema in mice. Respiratory Research, 2021, 22, 150.	3.6	7
32	Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.. Journal of Clinical Oncology, 2021, 39, e20590-e20590.	1.6	0
33	The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with nonâ€"small-cell lung cancer differ based on PD-L1 expression. European Journal of Cancer, 2021, 149, 73-81.	2.8	34
34	A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6â€"RET fusion gene and NF1/TP53 mutations. Lung Cancer, 2021, 156, 1-4.	2.0	7
35	Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset. JTO Clinical and Research Reports, 2021, 2, 100171.	1.1	5
36	Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis. Scientific Reports, 2021, 11, 11882.	3.3	14

#	Article	IF	Citations
37	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naÃ¯ve ALK-, ROS1-, or EGFR-altered Nonâ€“small Cell Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 1653-1662.	4.1	7
38	Survival of chemo-naÃ¯ve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. Japanese Journal of Clinical Oncology, 2021, 51, 1269-1276.	1.3	7
39	Triple therapy with osimertinib, bevacizumab and cetuximab in EGFRâ€‘mutant lung cancer with HIFâ€‘1Î±/TGFâ€Î± expression. Oncology Letters, 2021, 22, 639.	1.8	1
40	Chemopreventive effects and anti-tumorigenic mechanisms of 2,6-dimethoxy-1,4-benzoquinone, a constituent of Vitis coignetiae Pulliat (crimson glory vine, known as yamabudo in Japan), toward 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in A/J mice. Food and Chemical Toxicology, 2021, 154, 112319.	3.6	5
41	Dramatic Response to Carboplatin Plus Paclitaxel in Pancreatic Mucinous Cystadenocarcinoma with Liver Metastasis. Internal Medicine, 2021, 60, 2967-2971.	0.7	2
42	Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression. European Journal of Cancer, 2021, 157, 523-524.	2.8	0
43	Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L925-L940.	2.9	14
44	Crizotinib for recurring nonâ€smallâ€cell lung cancer with EML4â€ALK fusion genes previously treated with alectinib: A phase II trial. Thoracic Cancer, 2021, 12, 643-649.	1.9	5
45	Visceral Adipose Mass and Radiation Pneumonitis After Concurrent Chemoradiotherapy in Patients With Non-small-cell Lung Cancer. Cancer Diagnosis & Prognosis, 2021, 1, 61-67.	0.7	2
46	Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells. Experimental Cell Research, 2021, 409, 112940.	2.6	2
47	Transformed diffuse large B-cell lymphoma from marginal zone lymphoma in the anterior mediastinum: A case report and review of the literature. Journal of Clinical and Experimental Hematopathology: JCEH, 2021, 62, .	0.8	0
48	Volumetric PET Parameters Predict Prognosis after Definitive Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-Small Cell Lung Cancer. Acta Medica Okayama, 2021, 75, 15-23.	0.2	0
49	Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer. Acta Medica Okayama, 2021, 75, 269-277.	0.2	0
50	Managing Lung Cancer with Comorbid Interstitial Pneumonia. Internal Medicine, 2020, 59, 163-167.	0.7	14
51	Patientsâ€™ preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. Acta OncolÃ³gica, 2020, 59, 324-328.	1.8	2
52	Therapies after first-line afatinib in patients with EGFRm⁺ NSCLC in Japan: retrospective analysis of LUX-Lung 3. Future Oncology, 2020, 16, 49-60.	2.4	4
53	Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review. Internal Medicine, 2020, 59, 823-828.	0.7	9
54	The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer, 2020, 139, 140-145.	2.0	68

#	Article	IF	Citations
55	Nivolumab for the treatment of unresectable pleural mesothelioma. Expert Opinion on Biological Therapy, 2020, 20, 109-114.	3.1	11
56	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. Acta OncolÃ³gica, 2020, 59, 249-256.	1.8	28
57	Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. Biochemical and Biophysical Research Communications, 2020, 532, 341-346.	2.1	10
58	Utility of immune checkpoint inhibitors in nonâ€smallâ€cell lung cancer patients with poor performance status. Cancer Science, 2020, 111, 3739-3746.	3.9	20
59	Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. Lung Cancer, 2020, 150, 83-89.	2.0	9
60	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. Japanese Journal of Clinical Oncology, 2020, 50, 1447-1453.	1.3	14
61	Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for nonâ€small cell lung cancer: Analysis of doseâ€volume parameters. Cancer Medicine, 2020, 9, 4540-4549.	2.8	16
62	Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case. Internal Medicine, 2020, 59, 2023-2028.	0.7	4
63	Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. Lung Cancer, 2020, 146, 160-164.	2.0	6
64	Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database. Lung Cancer, 2020, 146, 236-243.	2.0	7
65	Pilot evaluation of a HER2 testing in non-small-cell lung cancer. Journal of Clinical Pathology, 2020, 73, 353-357.	2.0	12
66	Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. Respiratory Investigation, 2020, 58, 185-189.	1.8	5
67	Pulmonary aspergillosis as a late complication after surgery for locally advanced non-small cell lung cancer treated with induction chemoradiotherapy. Surgery Today, 2020, 50, 863-871.	1.5	6
68	Chemoradiation therapy for non-small cell lung cancer exacerbates thoracic aortic calcification determined by computed tomography. Heart and Vessels, 2020, 35, 1401-1408.	1.2	3
69	A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients. Cancer Science, 2020, 111, 1685-1691.	3.9	22
70	Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies. Acta Medica Okayama, 2020, 74, 371-379.	0.2	2
71	Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction. Oncology Letters, 2020, 20, 1-1.	1.8	4
72	RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).. Journal of Clinical Oncology, 2020, 38, 9527-9527.	1.6	1

#	Article	IF	Citations
73	Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab. Acta Medica Okayama, 2020, 74, 423-425.	0.2	2
74	Osimertinib for Japanese patients with T790Mâ€positive advanced nonâ€smallâ€cell lung cancer: A pooled subgroup analysis. Cancer Science, 2019, 110, 2884-2893.	3.9	22
75	A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an <i>EGFR</i> Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages. Internal Medicine, 2019, 58, 3033-3037.	0.7	7
76	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respiratory Investigation, 2019, 57, 512-533.	1.8	36
77	Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review. Respiratory Medicine Case Reports, 2019, 28, 100938.	0.4	9
78	A case of axillary lymphadenitis caused by Mycobacterium intracellulare in an immunocompetent patient. Respiratory Medicine Case Reports, 2019, 28, 100947.	0.4	0
79	Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer. In Vivo, 2019, 33, 2113-2115.	1.3	4
80	Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. Journal of Thoracic Oncology, 2019, 14, 2009-2018.	1.1	22
81	EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice. Lung Cancer, 2019, 136, 86-93.	2.0	7
82	Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, e168-e169.	1.1	9
83	Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab. Internal Medicine, 2019, 58, 985-989.	0.7	25
84	Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib. Internal Medicine, 2019, 58, 1625-1627.	0.7	3
85	Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation. Japanese Journal of Clinical Oncology, 2019, 49, 786-788.	1.3	13
86	Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. Respiratory Investigation, 2019, 57, 460-465.	1.8	2
87	Cause of pleuroparenchymal fibroelastosis following allogeneic hematopoietic stem cell transplantation. Respiratory Investigation, 2019, 57, 321-324.	1.8	19
88	A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY). Chest, 2019, 156, 357-366.	0.8	25
89	The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2019, 49, 762-765.	1.3	43
90	Recent trends in the treatment of unresectable stage III non-small-cell lung cancer. Respiratory Investigation, 2019, 57, 330-336.	1.8	5

#	Article	IF	Citations
91	Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. International Journal of Clinical Oncology, 2019, 24, 461-467.	2.2	7
92	Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. Japanese Journal of Clinical Oncology, 2019, 49, 458-464.	1.3	17
93	A phase I/II trial of weekly nabâ€paclitaxel for pretreated nonâ€smallâ€cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 250-256.	1.1	3
94	Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. Lung Cancer, 2019, 132, 54-58.	2.0	15
95	Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy. Surgery Today, 2019, 49, 601-609.	1.5	8
96	Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis. BMC Cancer, 2019, 19, 1144.	2.6	12
97	Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. International Journal of Clinical Oncology, 2019, 24, 41-45.	2.2	5
98	Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival. Respiratory Investigation, 2019, 57, 165-171.	1.8	10
99	Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Nonâ€“Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. Clinical Lung Cancer, 2019, 20, 134-138.	2.6	19
100	Requirement for neuropeptide Y in the development of type 2 responses and allergen-induced airway hyperresponsiveness and inflammation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L407-L417.	2.9	21
101	A retinoid X receptor partial agonist attenuates pulmonary emphysema and airway inflammation. Respiratory Research, 2019, 20, 2.	3.6	28
102	Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.. Journal of Clinical Oncology, 2019, 37, 9056-9056.	1.6	1
103	Randomized phase II study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in advanced non-small cell lung cancer: The OLCSG1406 trial.. Journal of Clinical Oncology, 2019, 37, e23105-e23105.	1.6	1
104	Tumor microenvironment affecting the effect of immuno-checkpoint inhibitors. Okayama Igakkai Zasshi, 2019, 131, 51-53.	0.0	0
105	Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. Japanese Journal of Clinical Oncology, 2018, 48, 367-375.	1.3	26
106	Osimertinib in patients with epidermal growth factor receptor T790M advanced nonâ€small cell lung cancer selected using cytology samples. Cancer Science, 2018, 109, 1177-1184.	3.9	10
107	Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab. Allergology International, 2018, 67, 521-523.	3.3	21
108	Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. Japanese Journal of Clinical Oncology, 2018, 48, 287-290.	1.3	3

#	Article	IF	Citations
109	MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. Scientific Reports, 2018, 8, 1955.	3.3	34
110	Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR -Mutant Metastatic Nonâ€“Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clinical Lung Cancer, 2018, 19, 213-220.e4.	2.6	13
111	A Phase II Study of Trastuzumab Emtansine in HER2-Positive Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 273-279.	1.1	119
112	A phase I trial of afatinib and bevacizumab in chemo-naÃ¯ve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. Lung Cancer, 2018, 115, 103-108.	2.0	25
113	Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. Biochemical and Biophysical Research Communications, 2018, 495, 360-367.	2.1	15
114	Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E. Oncologist, 2018, 23, 150-154.	3.7	25
115	Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion?. Annals of Thoracic and Cardiovascular Surgery, 2018, 24, 131-138.	0.8	2
116	A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. Cancer Chemotherapy and Pharmacology, 2018, 82, 1031-1038.	2.3	18
117	Combined effect of cabozantinib and gefitinib in crizotinibâ€resistant lung tumors harboring <scp>ROS</scp>1 fusions. Cancer Science, 2018, 109, 3149-3158.	3.9	20
118	Needle wash solution cultures following EBUS-TBNA with or without endobronchial intubation. Respiratory Investigation, 2018, 56, 356-360.	1.8	3
119	<scp>ASP</scp>8273 tolerability and antitumor activity in tyrosine kinase inhibitorâ€naÃ¯ve Japanese patients with <scp>EGFR</scp> mutationâ€positive nonâ€smallâ€cell lung cancer. Cancer Science, 2018, 109, 2532-2538.	3.9	10
120	A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors. Journal of Pharmaceutical Health Care and Sciences, 2018, 4, 2.	1.0	1
121	Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors. Clinical Lung Cancer, 2018, 19, e861-e864.	2.6	27
122	Osimertinib Depletes EGFRÂT790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M. Journal of Thoracic Oncology, 2018, 13, e140-e142.	1.1	6
123	Clinical activity of <scp>ASP</scp>8273 in Asian patients with nonâ€smallâ€cell lung cancer with <scp>EGFR</scp> activating and T790M mutations. Cancer Science, 2018, 109, 2852-2862.	3.9	15
124	The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e21147-e21147.	1.6	2
125	Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. Oncotarget, 2018, 9, 29525-29531.	1.8	28
126	Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors.. Journal of Clinical Oncology, 2018, 36, TPS3119-TPS3119.	1.6	0

#	Article	IF	Citations
127	Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients.. Journal of Clinical Oncology, 2018, 36, e21034-e21034.	1.6	0
128	Treatment for Advanced Squamous Cell Carcinoma of the Lung. Japanese Journal of Lung Cancer, 2018, 58, 325-330.	0.1	0
129	Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. Japanese Journal of Clinical Oncology, 2017, 47, 434-437.	1.3	6
130	Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin. Annals of Thoracic Surgery, 2017, 104, 971-978.	1.3	5
131	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 874-886.	10.7	453
132	Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset. Japanese Journal of Clinical Oncology, 2017, 47, 618-624.	1.3	14
133	Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790MinÂvivo. Molecular Oncology, 2017, 11, 670-681.	4.6	14
134	Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Nonâ€“Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol. Clinical Lung Cancer, 2017, 18, 245-249.	2.6	8
135	A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. Lung Cancer, 2017, 112, 188-194.	2.0	5
136	Clinical characteristics of Japanese candidates for lung transplant for interstitial lung disease and risk factors for early death while on the waiting list. Respiratory Investigation, 2017, 55, 264-269.	1.8	10
137	Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. Clinical Lung Cancer, 2017, 18, 241-244.	2.6	9
138	Trastuzumab Emtansine in HER2+ Recurrent Metastatic Nonâ€“Small-Cell Lung Cancer: Study Protocol. Clinical Lung Cancer, 2017, 18, 92-95.	2.6	19
139	Phase I/II study of alectinib in lung cancer with <i>RET</i> fusion gene: study protocol. Journal of Medical Investigation, 2017, 64, 317-320.	0.5	16
140	Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC). Internal Medicine, 2017, 56, 2195-2197.	0.7	38
141	Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease. International Journal of COPD, 2017, Volume 12, 1119-1124.	2.3	13
142	Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Nonâ€“Small-Cell Lung Cancer: AF-001JP. Journal of Clinical Oncology, 2017, 35, 1515-1521.	1.6	63
143	Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 3076-3086.	1.4	4
144	The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer.. Journal of Clinical Oncology, 2017, 35, e20601-e20601.	1.6	17

#	Article	IF	Citations
145	Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Acta Medica Okayama, 2017, 71, 453-457.	0.2	4
146	A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small cell lung cancer with wild type EGFR (OLCSG1202).. Journal of Clinical Oncology, 2017, 35, e20614-e20614.	1.6	0
147	Chemoradiotherapy (CRT) for locally-advanced (LA) lung cancer patients with interstitial lung abnormalities (ILA).. Journal of Clinical Oncology, 2017, 35, e20057-e20057.	1.6	0
148	Tolerability and antitumor activity of ASP8273 in TKI-naive Japanese subjects with EGFR mutationâ€“positive non-small cell lung cancer.. Journal of Clinical Oncology, 2017, 35, 9037-9037.	1.6	1
149	Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation. OncoTargets and Therapy, 2016, 9, 1753.	2.0	4
150	Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. Lung Cancer, 2016, 101, 1-8.	2.0	118
151	Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study. Japanese Journal of Clinical Oncology, 2016, 46, 871-874.	1.3	17
152	Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer. Experimental Cell Research, 2016, 344, 194-200.	2.6	9
153	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Cancer Chemotherapy and Pharmacology, 2016, 78, 941-947.	2.3	6
154	A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102. Cancer Chemotherapy and Pharmacology, 2016, 78, 769-774.	2.3	7
155	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Nonâ€“Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). Clinical Lung Cancer, 2016, 17, 602-605.	2.6	10
156	Pharmacokinetics of amrubicin in lung cancer patients with impaired hepatic function. Cancer Treatment and Research Communications, 2016, 9, 81-87.	1.7	0
157	The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy. Annals of Thoracic Surgery, 2016, 102, 985-992.	1.3	7
158	Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2016, 17, 1147-1157.	10.7	122
159	Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. Cancer Chemotherapy and Pharmacology, 2016, 77, 1005-1009.	2.3	14
160	Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography. Japanese Journal of Clinical Oncology, 2016, 46, 529-533.	1.3	2
161	Nonâ€“Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Cancer Research, 2016, 76, 1506-1516.	0.9	115
162	Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Nonâ€“Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol. Clinical Lung Cancer, 2016, 17, 75-79.	2.6	13

#	Article	IF	Citations
163	Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. International Journal of Clinical Oncology, 2016, 21, 81-87.	2.2	26
164	Second primary cancer in survivors of locally advanced NSCLC treated with concurrent chemoradiation followed by surgery.. Journal of Clinical Oncology, 2016, 34, 10100-10100.	1.6	0
165	Association with consolidation chemotherapy after concurrent chemoradiotherapyfollowed by surgery and the disease free survival in patients with stage III non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e20053-e20053.	1.6	0
166	Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. Japanese Journal of Clinical Oncology, 2015, 45, 603-4.	1.3	12
167	Downregulation of TBXAS 1 in an ironâ€induced malignant mesothelioma model. Cancer Science, 2015, 106, 1296-1302.	3.9	14
168	Lower lobe origin is a poor prognostic factor in locally advanced non-small-cell lung cancer patients treated with induction chemoradiotherapy. Molecular and Clinical Oncology, 2015, 3, 706-712.	1.0	18
169	Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers, 2015, 7, 763-783.	3.7	59
170	Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review. PLoS ONE, 2015, 10, e0121211.	2.5	16
171	TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells. PLoS ONE, 2015, 10, e0129838.	2.5	9
172	Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced nonâ€small cell lung cancer harboring activating <scp>EGFR</scp> mutations: Subgroup analysis of <scp>LUX</scp>â€Lung 3. Cancer Science, 2015, 106, 1202-1211.	3.9	99
173	Fever after lung radiofrequency ablation: Prospective evaluation of its incidence and associated factors. European Journal of Radiology, 2015, 84, 2202-2209.	2.6	5
174	Endobronchial ultrasound-guided transbronchial biopsy with or without a guide sheath for diagnosis of lung Cancer. Respiratory Investigation, 2015, 53, 93-97.	1.8	18
175	A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0501. Lung Cancer, 2015, 87, 141-147.	2.0	30
176	Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. Cancer Chemotherapy and Pharmacology, 2015, 76, 251-256.	2.3	11
177	Chemotherapy for lung cancer: still alive!. Japanese Journal of Clinical Oncology, 2015, 45, 609-610.	1.3	1
178	Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer. Journal of Pharmaceutical Health Care and Sciences, 2015, 1, 8.	1.0	17
179	Percutaneous Radiofrequency Ablation of Lung Cancer Presenting as Ground-Glass Opacity. CardioVascular and Interventional Radiology, 2015, 38, 409-415.	2.0	37
180	Phase II study of topotecan and cisplatin with sequential radiotherapy in elderly small cell lung cancer patients (Okayama Lung Cancer Study Group; OLCSG 0102).. Journal of Clinical Oncology, 2015, 33, 7572-7572.	1.6	1

#	Article	IF	Citations
181	A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP.. Journal of Clinical Oncology, 2015, 33, 8061-8061.	1.6	6
182	Development of skin rash within the 1st week is a potential surrogate marker of therapeutic effect in afatinib monotherapy in patients with EGFR-mt non-small-cell lung cancer (NSCLC): Okayama Lung Cancer Study Group Experience.. Journal of Clinical Oncology, 2015, 33, e19051-e19051.	1.6	1
183	Crizotinib to overcome alectinib-resistance in non-small cell lung cancer (NSCLC) harboring EML4-ALK.. Journal of Clinical Oncology, 2015, 33, e19140-e19140.	1.6	1
184	Publication of Lung Cancer Clinical Trials in Japan. Japanese Journal of Lung Cancer, 2015, 55, 1070-1074.	0.1	0
185	A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy. Okayama	0.0	1
186	Three-arm randomized trial of sodium alginate, orally administered mucoprotective agent, for preventing radiation esophagitis in pts with locally advanced non-small-cell lung cancer (LA-NSCLC) receiving concurrent chemoradiotherapy (CRT): Okayama Lung Cancer Study Group 1401.. Journal of Clinical Oncology, 2015, 33, TPS9641-TPS9641.	1.6	0
187	Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. American Journal of Cancer Research, 2015, 5, 1553-7.	1.4	11
188	Phase I/II Study of Alectinib (CH5424802/RO5424802) in Patients with ALK-rearranged Non-small Cell Lung Cancer (NSCLC): Updated Results from the AF-001JP Trial. Japanese Journal of Lung Cancer, 2014, 54, 892-897.	0.1	1
189	Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation. Drug Design, Development and Therapy, 2014, 8, 2401.	4.3	3
190	The Role of STAT3 in Non-Small Cell Lung Cancer. Cancers, 2014, 6, 708-722.	3.7	154
191	Rapid on-site evaluation with BIOEVALUATORÂ®during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing pulmonary and mediastinal diseases. Annals of Thoracic Medicine, 2014, 9, 14.	1.8	12
192	Current status and future perspectives of cooperative study groups for lung cancer in Japan. Respiratory Investigation, 2014, 52, 339-347.	1.8	3
193	A New Human Lung Adenocarcinoma Cell Line Harboring the EML4-ALK Fusion Gene. Japanese Journal of Clinical Oncology, 2014, 44, 963-968.	1.3	11
194	A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer, 2014, 84, 67-72.	2.0	62
195	Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. Lung Cancer, 2014, 83, 30-36.	2.0	30
196	Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Experimental Cell Research, 2014, 322, 168-177.	2.6	43
197	A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0801. European Journal of Cancer, 2014, 50, 2783-2790.	2.8	18
198	A Survey of Japanese Thoracic Oncologists' Perception of Diagnostic and Treatment Strategies for EGFR Mutant or EML4-ALK Fusion Non-small Cell Lung Cancer. Chest, 2014, 146, e222-e225.	0.8	4

#	Article	IF	Citations
199	A randomized phase III study of cisplatin (CDDP), etoposide (ETOP) and irinotecan versus topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC): Japan Clinical Oncology Group study JCOG0605. Journal of Clinical Oncology, 2014, 32, 7504-7504.	1.6	3
200	Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC.. Journal of Clinical Oncology, 2014, 32, e19102-e19102.	1.6	0
201	Time trend in the survival advantage in phase III trials investigating molecular-targeted agents for advanced non-small cell lung cancer (NSCLC) during the past decade.. Journal of Clinical Oncology, 2014, 32, e19084-e19084.	1.6	0
202	A phase II study of S-1 and concurrent thoracic radiotherapy (TRT) for elderly pts with locally advanced non-small cell lung cancer (LA-NSCLC): Okayama Lung Cancer Study Group trial 0801.. Journal of Clinical Oncology, 2014, 32, 7576-7576.	1.6	0
203	Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer, 2013, 81, 435-439.	2.0	28
204	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1â€“2 study. Lancet Oncology, The, 2013, 14, 590-598.	10.7	555
205	Reappraisal of Short-term Low-volume Hydration in Cisplatin-based Chemotherapy: Results of a Prospective Feasibility Study in Advanced Lung Cancer in the Okayama Lung Cancer Study Group Trial 1002. Japanese Journal of Clinical Oncology, 2013, 43, 1115-1123.	1.3	48
206	Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptorâ€mutated lung cancer model. Cancer Science, 2013, 104, 1440-1446.	3.9	34
207	Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model. Molecular Cancer Therapeutics, 2013, 12, 589-597.	4.1	62
208	New treatment strategy for patients withEGFR-mutant lung cancer. Lung Cancer Management, 2013, 2, 505-516.	1.5	0
209	A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP.. Journal of Clinical Oncology, 2013, 31, 8033-8033.	1.6	14
210	Impact of body surface area (BSA) on efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19167-e19167.	1.6	0
211	Survival analysis of induction cisplatin (CDDP)-docetaxel (DOC)-bevacizumab (BEV) chemotherapy followed by maintenance BEV-pemetrexed (PEM) therapy in advanced nonsquamous non-small cell lung cancer (NonSq NSCLC): A phase II trial from Okayama Lung Cancer Study Group 0903.. Journal of Clinical Oncology, 2013, 31, e19040-e19040.	1.6	0
212	Prospective cohort study of serum sialylated glycoprotein (KL-6) as a prognostic marker in patients (pts) with non-small cell lung cancer (NSCLC) receiving gefitinib monotherapy: Okayama Lung Cancer Study Group 0703.. Journal of Clinical Oncology, 2013, 31, e19023-e19023.	1.6	0
213	A survey on Japanese thoracic oncologistsâ€™ preference on treatment strategy for EGFR-mutant or EML4-ALK-mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19124-e19124.	1.6	0
214	STAT3 expression in activating EGFR-driven adenocarcinoma of the lung. Lung Cancer, 2012, 75, 24-29.	2.0	19
215	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2127-33.	7.1	410
216	<scp>JAK</scp>2â€related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptorâ€activating mutation. Cancer Science, 2012, 103, 1795-1802.	3.9	40

#	Article	IF	Citations
217	Impact of body surface area on efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutation.. Journal of Clinical Oncology, 2012, 30, 2607-2607.	1.6	1
218	A phase II trial of induction gefitinib monotherapy followed by cisplatin-docetaxel and concurrent thoracic irradiation in patients with EGFR-mutant locally advanced non-small-cell lung cancer (LA-NSCLC): LOGIK0902/OLCSG0905 intergroup trial.. Journal of Clinical Oncology, 2012, 30, 7045-7045.	1.6	2
219	A first-in-human phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC.. Journal of Clinical Oncology, 2012, 30, 7602-7602.	1.6	5
220	A randomized phase III study of a cisplatin (CDDP) and docetaxel (DOC) with or without irinotecan (CPT) in pts with advanced NSCLC: Okayama Lung Cancer Study Group OLCSG 0403 trial.. Journal of Clinical Oncology, 2012, 30, 7560-7560.	1.6	0
221	Survival post-progression (SPP) in phase III trials of chemotherapy in advanced NSCLC: Its potentially different impact on OS in the first-line and salvage settings.. Journal of Clinical Oncology, 2012, 30, e18027-e18027.	1.6	0
222	A phase II study of cisplatin (P), S-1 (S), and concurrent thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (LA-NSCLC): Okayama Lung Cancer Study Group trial 0501.. Journal of Clinical Oncology, 2012, 30, 7042-7042.	1.6	0
223	Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: Okayama Lung Cancer Study Group experience.. Journal of Clinical Oncology, 2012, 30, 7576-7576.	1.6	0
224	Cavitary pulmonary involvement of diffuse large B-cell lymphoma transformed from extra nodal marginal zone B-cell lymphoma MALT type. Clinical Journal of Gastroenterology, 2011, 4, 401-406.	0.8	4
225	An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report. World Journal of Clinical Oncology, 2011, 2, 299.	2.3	6
226	Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience. Journal of Thoracic Oncology, 2010, 5, 179-184.	1.1	69
227	Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Nonâ€“Small-Cell Lung Cancer: OLCSG 0007. Journal of Clinical Oncology, 2010, 28, 3299-3306.	1.6	225
228	Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Lung Cancer, 2010, 70, 308-312.	2.0	8
229	Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo. Cancer Research, 2009, 69, 5091-5098.	0.9	65
230	Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice. Cancer Research, 2009, 69, 7088-7095.	0.9	23
231	Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice. Lung Cancer, 2009, 65, 284-289.	2.0	9
232	Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer, 2009, 66, 107-113.	2.0	20
233	Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SPâ€€ promoter. Cancer Science, 2008, 99, 1747-1753.	3.9	27
234	Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer. Lung Cancer, 2008, 62, 236-241.	2.0	9

#	Article	IF	Citations
235	A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 386-393.	1.1	88
236	IIã€€è‚ºç™Œã®å†…ç§‘çš„æ²»ç™‚. Okayama Igakkai Zasshi, 2008, 119, 285-292.	0.0	0
237	Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib. , 2008, , 307-316.		1
238	The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 5763-5768.	7.0	81
239	Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Nonâ€“Small Cell Lung Cancer Cell Line. Cancer Research, 2007, 67, 7807-7814.	0.9	170
240	The Effect of Gefitinib on B-RAF Mutant Non-small Cell Lung Cancer and Transfectants. Journal of Thoracic Oncology, 2007, 2, 321-324.	1.1	5
241	Triple Combination Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Advanced Non-small Cell Lung Cancer: A Phase I/II Trial. Journal of Thoracic Oncology, 2007, 2, 44-50.	1.1	5
242	Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. Lung Cancer, 2007, 58, 30-35.	2.0	20
243	Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung. Journal of Clinical Oncology, 2007, 25, 3952-3957.	1.6	42
244	Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy. Lung Cancer, 2007, 55, 343-348.	2.0	5
245	Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Science, 2007, 98, 357-363.	3.9	48
246	Presence of Epidermal Growth Factor Receptor Gene T790M Mutation as a Minor Clone in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2006, 66, 7854-7858.	0.9	422
247	Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. Journal of Cancer Research and Clinical Oncology, 2005, 131, 147-151.	2.5	35
248	Can dose-dense chemotherapy improve outcome in patients with better-prognosis small-cell lung cancer?. Nature Clinical Practice Oncology, 2005, 2, 610-611.	4.3	0
249	The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clinical Cancer Research, 2005, 11, 1167-73.	7.0	344
250	Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2004, 22, 3852-3859.	1.6	373
251	Effect of gefitinib (â€˜Iressaâ€™, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer, 2004, 46, 255-261.	2.0	175
252	Dramatic effect of ZD1839 (â€˜Iressaâ€™) in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer, 2003, 40, 73-76.	2.0	54

#	Article	IF	Citations
253	A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer, 2002, 36, 313-319.	2.0	17
254	Lamivudine and Glycyrrhizin for Treatment of Chemotherapy-Induced Hepatitis B Virus (HBV) Hepatitis in a Chronic HBV Carrier with Non-Hodgkin Lymphoma. Leukemia and Lymphoma, 2001, 41, 191-195.	1.3	28